AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00000434 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fit and Strong!
Description: Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
Study NCT03261180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive regular diet
Study NCT05762744 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Exenatide Injection
Description: Nurses administered exenatide (5 mcg) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
Study NCT05762744 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Saline injection
Description: Nurses administered saline (0.2 mL) subcutaneously 15 minutes prior to conducting a frequently sampled intravenous glucose tolerance test.
Study NCT02961205 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutritional Supplementation
Description: Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.~After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge.
Study NCT01083797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine
Description: 1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
Study NCT01083797 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Chloral Hydrate
Description: Initial dose=50 mg/kg
Study NCT06348277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness plus mood monitoring
Description: mobile app that provides guided mindfulness exercises in addition to prompting for mood monitoring three times per day
Study NCT04221074 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS II versus ESP
Description: compare between :ultrasound guided Pectoralis nerve(pecs) II block or erector spinae plane (ESP) block in surgical treatment for gynecomastia patients under general anaesthesia.
Study NCT03285880 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Napping
Description: Children nap during the nap opportunity
Study NCT06348277 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mood monitoring
Description: mobile app that prompts for mood monitoring three times per day
Study NCT01102127 — intervention group
Intervention type: DEVICE
Intervention: Elastography
Description: Performance of US, elastography and FNA.
Study NCT01286805 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lumbar Plexus Blockade
Description: The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
Study NCT01286805 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: The control group will receive only a combined spinal-epidural.
Study NCT02161549 — intervention group
Intervention type: DEVICE
Intervention: Motus Gl CleanUp System
Study NCT03402867 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Deep dry needling
Description: Insertion of a filiform needle in the active trigger point of musculoskeletal muscle
Study NCT03527056 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplantation
Description: This is a parallel arm study. All participants in the experimental arm will receive a single fecal transplantation via oral capsules to determine effectiveness and safety in decolonizing gastrointestinal CRE.
Study NCT02886676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Spirulina capsules
Description: Spirulina capsules 2gm daily for 1 month
Study NCT00935857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Single Balloon Colonoscopy
Description: Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
Study NCT00935857 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Colonoscopy
Description: Use of the standard adult colonoscope to complete colonoscopy.
Study NCT03261180 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03261180 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03261180 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutritional Intervention
Description: Receive Nestle Impact AR
Study NCT02090868 — intervention group
Intervention type: OTHER
Intervention: Oral Intake Screening Tool
Description: A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
Study NCT03028350 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ifetroban Oral Capsule
Description: Subjects will be treated with oral ifetroban daily for 8 weeks
Study NCT03028350 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Capsule
Description: Subjects will be treated with oral placebo daily for 8 weeks
Study NCT02156531 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Administered, Active Cognitive Bias Modification (CBM)
Description: Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
Study NCT02886676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spirulina capsules
Description: Spirulina capsules 2gm daily for 1 month
Study NCT02144805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suturing in a single layer
Description: The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
Study NCT02144805 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Suturing in two layer
Description: The procedure define the use of two sutures for closing the uterine incision following cesarean section
Study NCT02678780 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Study NCT02159820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Decitabine (DTC Arm)
Description: Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
Study NCT02156531 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-Administered, minimally effective attention-control version of the CBM program
Description: Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
Study NCT02972372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CRT
Description: Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total~Other Names:~Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.~Other Names:~Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.~Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
Study NCT02972372 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
Study NCT04547413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: STI/HIV Intervention Behavioral Intervention Program
Description: In addition to standard of care STi/HIV counselling, participants in the intervention arm will also attend a 2-hour educational class and will receive monthly SMS/text messages to reinforce the content of the class.
Study NCT04633460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: A nutraceutical ketone ester (KE), (R)-3-hydroxybutyl (R)-3-hydroxybutyrate which provides systemic ketosis
Study NCT01244334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Difluprednate ophthalmic emulsion 0.05%
Description: Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
Study NCT01244334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone acetate 1%
Description: Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
Study NCT01993329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 50 mg
Description: Gefapixant 50 mg tablet administered orally
Study NCT01993329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefapixant 300 mg
Description: Gefapixant 300 mg tablet administered orally
Study NCT04633460 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo drink
Description: KE free placebo drink
Study NCT01993329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 50 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 50 mg tablets
Study NCT02159820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel and Carboplatin (TC Arm)
Description: The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve \[AUC\] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
Study NCT02208336 — intervention group
Intervention type: OTHER
Intervention: medical chart review
Description: Ancillary studies
Study NCT03410823 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PUSH
Description: Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
Study NCT03410823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein
Description: Participants will receive a whey-based protein supplement in the form of a powder containing 27.6g of protein. This dose induces maximum muscle protein synthesis post-exercise. Participants will mix the supplement in 8 oz of water (or other beverage) or soft food (e.g., yogurt, soup) and consume immediately following each exercise session with the study PT. On days when they do not have a physical therapy visit with the study PT, participants will be instructed to take the supplement at the meal time closest to the time of scheduled PT visits to maintain regular daily dosing schedule.
Study NCT03410823 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutrition
Description: Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at baseline to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of baseline testing Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
Study NCT03022656 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Brace system
Study NCT01995370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clopidogrel
Description: Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study NCT01995370 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clopidogrel
Description: Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study NCT01995370 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cilostazol
Description: Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
Study NCT00684502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
Study NCT00684502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
Study NCT02365896 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: TLDG or LADG
Study NCT00347048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: oral
Study NCT00347048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral
Study NCT03390244 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Foldable Capsular Vitreous Body Implant
Description: Vitrectomy augmented with the implantation of the FCVB implant
Study NCT04201015 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart rate optimisation using force frequency data
Description: Programming heart rate rise according to the force frequency relationship
Study NCT04201015 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart rate optimisation using force frequency data
Description: Programming heart rate rise according to the force frequency relationship
Study NCT02570854 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSJ137
Description: Starting dose is 0.010 mg/kg and dose escalation will proceed with semi-log increase steps to a maximum dose level 10 mg/kg. Subjects receive the treatment via up to 30 minutes intravenous infusion.
Study NCT02570854 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be dosed with a matching placebo (vehicle control) via up to 30 minutes intravenous infusion.
Study NCT00139815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Description: fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
Study NCT00139815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin
Description: enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
Study NCT00991692 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapy services (ACQUIREc Therapy)
Description: Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
Study NCT01044134 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary counseling
Description: Participants will receive personalized dietary counseling to promote behavior change
Study NCT01044134 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dietary counseling
Description: Participants will receive personalized dietary counseling to promote behavior change
Study NCT02490800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisavanbulin Phase 1 dose escalation portion
Description: Lisavanbulin hard capsules, containing 1 mg or 5 mg study drug, were given orally to fasted patients once daily in the dose range of 2 to 35 mg/day
Study NCT02490800 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lisavanbulin Phase 2a expansion portion
Description: Recommended Phase 2 dose (RP2D) of 25 mg/day lisavanbulin hard capsules containing 5 mg study drug was administered once daily.
Study NCT01993329 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to mimic 300 mg tablets
Description: Sugar pill manufactured to mimic gefapixant 300 mg tablets
Study NCT01844700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ziprasidone
Description: random assignment to ZIP (20-160mg/d, bid dosing)
Study NCT01844700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole, quetiapine, or risperidone
Description: random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
Study NCT00854763 — intervention group
Intervention type: DRUG
Intervention: olmesartan
Description: olmesartan
Study NCT01270672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3,4-Methylenedioxymethamphetamine
Description: 125 mg per os, single dose
Study NCT01270672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carvedilol
Description: 50 mg per os, single dose
Study NCT01270672 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: capsules identical to MDMA or carvedilol
Study NCT03711838 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine
Description: N-Acetylcysteine in a powder form diluted in a 250 ml drink containing 248 ml water and 2 ml of natural, non-caloric, flavoring-sweetener containing sucralose.
Study NCT00960440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
Study NCT00960440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
Study NCT00960440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
Study NCT00960440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
Study NCT00960440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
Study NCT00960440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CP-690,550
Description: Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
Study NCT01935908 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levetiracetam
Study NCT03125746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15029
Description: The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
Study NCT03125746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LXI-15029+Exemestane
Description: The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation